Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination

J Steitz1, D Tormo, D Schweichel

  • 1Department of Dermatology, Laboratory of Experimental Dermatology, University of Bonn, Bonn, Germany.

Cancer Gene Therapy
|September 10, 2005
PubMed

Optimal strategies for antigen-specific melanoma vaccination are currently being defined in experimental mouse models. Using a single H2-K(b)-binding peptide epitope derived from the melanosomal enzyme tyrosinase-related protein 2 (TRP2) in C57BL/6 mice, we show that adenovirus-transduced dendritic cells (DC) are clearly superior to peptide-pulsed DC for the induction of CD8+ T cells and antimelanoma immunity. Vaccine efficacy strictly depended on the presence of linked CD4+ T-cell help during the priming but not the effector phase of the immune response. These results provide important information for the translation of melanoma vaccine strategy in future clinical applications.